Literature DB >> 15925269

Treatment during transition from prison to community and subsequent illicit drug use.

Clifford A Butzin1, Steven S Martin, James A Inciardi.   

Abstract

This study examined the effects of postrelease transitional therapeutic community treatment on the drug use and employment rates of drug involved prisoners in the Delaware corrections system followed for up to 5 years after release. A comparison group received standard postrelease supervision. Abstinence rates were 32.2% in the treatment group and 9.9% in the no-treatment group, and the treatment group had a higher overall proportion of time free of drug use. Time to relapse was a mean of 28.8 months in the treatment group versus 13.2 months in the no-treatment group. Relapse was defined as any use of any drug and was confirmed by urinalysis. Positive effects were seen even for those who did not complete treatment. The treatment group had a significantly higher rate of employment after leaving work release (54.6%) than did the no-treatment group (45.4%). Treatment during the transitional period between prison and community showed substantial and persistent benefits even for a cohort marked with extensive criminal history, low rates of marital bonds, and substantial unemployment.

Mesh:

Substances:

Year:  2005        PMID: 15925269     DOI: 10.1016/j.jsat.2005.02.009

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  17 in total

1.  Effects of experimental Unemployment, Employment and Punishment analogs on opioid seeking and consumption in heroin-dependent volunteers.

Authors:  Mark K Greenwald
Journal:  Drug Alcohol Depend       Date:  2010-05-26       Impact factor: 4.492

2.  Differential outcomes of court-supervised substance abuse treatment among California parolees and probationers.

Authors:  Elizabeth Evans; Adi Jaffe; Darren Urada; M Douglas Anglin
Journal:  Int J Offender Ther Comp Criminol       Date:  2011-04-24

3.  Ukrainian prisoners and community reentry challenges: implications for transitional care.

Authors:  Olga Morozova; Lyuba Azbel; Yevgeny Grishaev; Sergii Dvoryak; Jeffrey A Wickersham; Frederick L Altice
Journal:  Int J Prison Health       Date:  2013

4.  Organizational characteristics of drug abuse treatment programs for offenders.

Authors:  Christine E Grella; Lisa Greenwell; Michael Prendergast; David Farabee; Elizabeth Hall; Jerome Cartier; William Burdon
Journal:  J Subst Abuse Treat       Date:  2007-03-09

5.  Are Washington Circle performance measures associated with decreased criminal activity following treatment?

Authors:  Deborah W Garnick; Constance M Horgan; Margaret T Lee; Lee Panas; Grant A Ritter; Steve Davis; Tracy Leeper; Rebecca Moore; Mark Reynolds
Journal:  J Subst Abuse Treat       Date:  2007-05-23

Review 6.  William L. Woolverton: a case history in unraveling the behavioral pharmacology of stimulants.

Authors:  Michael A Nader; Robert L Balster; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2014-05-20       Impact factor: 5.250

Review 7.  Natural rewards, neuroplasticity, and non-drug addictions.

Authors:  Christopher M Olsen
Journal:  Neuropharmacology       Date:  2011-04-01       Impact factor: 5.250

8.  Effectiveness of Using Incentives to Improve Parolee Admission and Attendance in Community Addiction Treatment.

Authors:  Michael L Prendergast; Elizabeth A Hall; Jason Grossman; Robert Veliz; Liliana Gregorio; Umme S Warda; Kory Van Unen; Chloe Knight
Journal:  Crim Justice Behav       Date:  2015-07-10

9.  Until I get off parole … then I can swim in it if I want to: Facilitators of and barriers to drug use among formerly incarcerated Black drug offenders.

Authors:  Rahma Mkuu; Tawandra L Rowell-Cunsolo; Idethia Shevon Harvey
Journal:  J Ethn Subst Abuse       Date:  2017-06-30       Impact factor: 1.507

10.  The association between social stressors and drug use/hazardous drinking among former prison inmates.

Authors:  Susan L Calcaterra; Brenda Beaty; Shane R Mueller; Sung-Joon Min; Ingrid A Binswanger
Journal:  J Subst Abuse Treat       Date:  2014-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.